# Elena Gonzalez-Rey

List of Publications by Year
in descending order



| 100 | 10,041 | 61945 | 33869 |
|---|---|---|---|
| papers | citations | 43 h-index | 99 g-index |

| 107 | 107 | 107 | 16604 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Robust In Vitro and In Vivo Immunosuppressive and Anti-inflammatory Properties of Inducible Caspase-9-mediated Apoptotic Mesenchymal Stromal/Stem Cell. Stem Cells Translational Medicine, 2022, 11, 88-96. | 1.6 | 4 |
| 2 | Switching Roles: Beneficial Effects of Adipose Tissue-Derived Mesenchymal Stem Cells on Microglia and Their Implication in Neurodegenerative Diseases. Biomolecules, 2022, 12, 219. | 1.8 | 5 |
| 3 | Efficacy of Vafidemstat in Experimental Autoimmune Encephalomyelitis Highlights the KDM1A/RCOR1/HDAC Epigenetic Axis in Multiple Sclerosis. Pharmaceutics, 2022, 14, 1420. | 2.0 | 3 |
| 4 | Structure-based design of a Cortistatin analogue with immunomodulatory activity in models of inflammatory bowel disease. Nature Communications, 2021, 12, 1869. | 5.8 | 16 |
| 5 | The Neuropeptide Cortistatin Alleviates Neuropathic Pain in Experimental Models of Peripheral Nerve Injury. Pharmaceutics, 2021, 13, 947. | 2.0 | 7 |
| 6 | Silyl resveratrol derivatives as potential therapeutic agents for neurodegenerative and neurological diseases. European Journal of Medicinal Chemistry, 2021, 223, 113655. | 2.6 | 12 |
| 7 | Bone marrow mesenchymal stem/stromal cells from risk-stratified acute myeloid leukemia patients are anti-inflammatory in in vivo preclinical models of hematopoietic reconstitution and severe colitis. Haematologica, 2019, 104, e54-e58. | 1.7 | 12 |
| 8 | Vasoactive Intestinal Peptide Ameliorates Acute Myocarditis and Atherosclerosis by Regulating Inflammatory and Autoimmune Responses. Journal of Immunology, 2018, 200, 3697-3710. | 0.4 | 22 |
| 9 | Autophagic-related cell death of Trypanosoma brucei induced by bacteriocin AS-48. International Journal for Parasitology: Drugs and Drug Resistance, 2018, 8, 203-212. | 1.4 | 27 |
| 10 | Alkylated resveratrol prodrugs and metabolites as potential therapeutics for neurodegenerative diseases. European Journal of Medicinal Chemistry, 2018, 146, 123-138. | 2.6 | 60 |
| 11 | Therapeutic effect of the immunomodulatory drug lenalidomide, but not pomalidomide, in experimental models of rheumatoid arthritis and inflammatory bowel disease. Experimental and Molecular Medicine, 2017, 49, e290-e290. | 3.2 | 21 |
| 12 | Cortistatin reduces atherosclerosis in hyperlipidemic ApoE-deficient mice and the formation of foam cells. Scientific Reports, 2017, 7, 46444. | 1.6 | 23 |
| 13 | Role of Cortistatin in the Stressed Immune System. Frontiers of Hormone Research, 2017, 48, 110-120. | 1.0 | 12 |
| 14 | The neuropeptide cortistatin attenuates experimental autoimmune myocarditis via inhibition of cardiomyogenic T cellâ€driven inflammatory responses. British Journal of Pharmacology, 2017, 174, 267-280. | 2.7 | 20 |
| 15 | Allogeneic Adipose-Derived Mesenchymal Stromal Cells Ameliorate Experimental Autoimmune Encephalomyelitis by Regulating Self-Reactive T Cell Responses and Dendritic Cell Function. Stem Cells International, 2017, 2017, 1-15. | 1.2 | 42 |
| 16 | Ghrelin and adipose-derived mesenchymal stromal cells improve nerve regeneration in a rat model of epsilon-caprolactone conduit reconstruction. Histology and Histopathology, 2017, 32, 627-637. | 0.5 | 5 |
| 17 | Lulling immunity, pain, and stress to sleep with cortistatin. Annals of the New York Academy of Sciences, 2015, 1351, 89-98. | 1.8 | 19 |
| 18 | Osteoarticular Expression of Musashi-1 in an Experimental Model of Arthritis. BioMed Research International, 2015, 2015, 1-9. | 0.9 | 9 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Therapeutic Efficacy of Stable Analogues of Vasoactive Intestinal Peptide against Pathogens. Journal of Biological Chemistry, 2014, 289, 14583-14599. | 1.6 | 37 |
| 20 | Mesenchymal stem cells induce the ramification of microglia via the small RhoGTPases Cdc42 and Rac1. Glia, 2014, 62, 1932-1942. | 2.5 | 45 |
| 21 | Human Bone Marrow Stromal Cells Lose Immunosuppressive and Anti-inflammatory Properties upon Oncogenic Transformation. Stem Cell Reports, 2014, 3, 606-619. | 2.3 | 33 |
| 22 | Therapeutic Effect of Human Amniotic Membraneâ€"Derived Cells on Experimental Arthritis and Other Inflammatory Disorders. Arthritis and Rheumatology, 2014, 66, 327-339. | 2.9 | 78 |
| 23 | Adrenomedullin protects from experimental autoimmune encephalomyelitis at multiple levels. Brain, Behavior, and Immunity, 2014, 37, 152-163. | 2.0 | 22 |
| 24 | Dual investigation of lanthanide complexes with cinnamate and phenylacetate ligands: Study of the cytotoxic properties and the catalytic oxidation of styrene. Polyhedron, 2014, 80, 117-128. | 1.0 | 19 |
| 25 | Therapeutic Application of Mesenchymal Stromal Cells in Murine Models of Inflammatory Bowel Disease. Methods in Molecular Biology, 2014, 1213, 331-339. | 0.4 | 6 |
| 26 | Therapeutic effect of ghrelin in experimental autoimmune encephalomyelitis by inhibiting antigen-specific Th1/Th17 responses and inducing regulatory T cells. Brain, Behavior, and Immunity, 2013, 30, 54-60. | 2.0 | 27 |
| 27 | Protective Role of the Neuropeptide Urocortin II against Experimental Sepsis and Leishmaniasis by Direct Killing of Pathogens. Journal of Immunology, 2013, 191, 6040-6051. | 0.4 | 17 |
| 28 | Adipose-derived mesenchymal stromal cells induce immunomodulatory macrophages which protect from experimental colitis and sepsis. Gut, 2013, 62, 1131-1141. | 6.1 | 182 |
| 29 | Analgesic Effect of the Neuropeptide Cortistatin in Murine Models of Arthritic Inflammatory Pain. Arthritis and Rheumatism, 2013, 65, 1390-1401. | 6.7 | 24 |
| 30 | LABCG2, a New ABC Transporter Implicated in Phosphatidylserine Exposure, Is Involved in the Infectivity and Pathogenicity of Leishmania. PLoS Neglected Tropical Diseases, 2013, 7, e2179. | 1.3 | 23 |
| 31 | Paradoxical Effect of Cortistatin Treatment and Its Deficiency on Experimental Autoimmune Encephalomyelitis. Journal of Immunology, 2013, 191, 2144-2154. | 0.4 | 32 |
| 32 | Preconditioning of Microglia by Î±-Synuclein Strongly Affects the Response Induced by Toll-like Receptor (TLR) Stimulation. PLoS ONE, 2013, 8, e79160. | 1.1 | 92 |
| 33 | VIP in Neurological Diseases: More Than A Neuropeptide. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2012, 12, 323-332. | 0.6 | 11 |
| 34 | Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 2012, 8, 445-544. | 4.3 | 3,122 |
| 35 | New Enzymes as Potential Therapeutic Targets for Trypanosomiases and Leishmaniasis. Enzyme Research, 2011, 2011, 1-1. | 1.8 | 1 |
| 36 | Neuropeptides as Pleiotropic Modulators of the Immune Response. Neuroendocrinology, 2011, 94, 89-100. | 1.2 | 91 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Human adipose-derived mesenchymal stem cells reduce inflammatory and T cell responses and induce regulatory T cells in vitro in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2010, 69, 241-248. | 0.5 | 372 |
| 38 | Keeping the Balance between Immune Tolerance and Pathogen Immunity with Endogenous Neuropeptides. NeuroImmunoModulation, 2010, 17, 161-164. | 0.9 | 7 |
| 39 | Neuropeptides as Therapeutic Approach to Autoimmune Diseases. Current Pharmaceutical Design, 2010, 16, 3158-3172. | 0.9 | 18 |
| 40 | Vasoactive Intestinal Peptide Induces Cell Cycle Arrest and Regulatory Functions in Human T Cells at Multiple Levels. Molecular and Cellular Biology, 2010, 30, 2537-2551. | 1.1 | 49 |
| 41 | Inhaled Vasoactive Intestinal Peptide Exerts Immunoregulatory Effects in Sarcoidosis. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 540-548. | 2.5 | 146 |
| 42 | Apoptosis induced by parasitic diseases. Parasites and Vectors, 2010, 3, 106. | 1.0 | 45 |
| 43 | Impact of protozoan cell death on parasite-host interactions and pathogenesis. Parasites and Vectors, 2010, 3, 116. | 1.0 | 41 |
| 44 | Neuropeptides: keeping the balance between pathogen immunity and immune tolerance. Current Opinion in Pharmacology, 2010, 10, 473-481. | 1.7 | 32 |
| 45 | Glial Innate Immunity Generated by Non-Aggregated Alpha-Synuclein in Mouse: Differences between Wild-type and Parkinson's Disease-Linked Mutants. PLoS ONE, 2010, 5, e13481. | 1.1 | 89 |
| 46 | Autophagy and neuropeptides at the crossroad for parasites: To survive or to die?. Autophagy, 2009, 5, 551-554. | 4.3 | 12 |
| 47 | Induction of Alloantigen-Specific Human T Regulatory Cells by Vasoactive Intestinal Peptide. Journal of Immunology, 2009, 183, 4346-4359. | 0.4 | 48 |
| 48 | Toll-like receptor stimulation differentially regulates vasoactive intestinal peptide type 2 receptor in macrophages. Journal of Cellular and Molecular Medicine, 2009, 13, 3209-3217. | 1.6 | 18 |
| 49 | Treatment of experimental arthritis by inducing immune tolerance with human adiposeâ€derived mesenchymal stem cells. Arthritis and Rheumatism, 2009, 60, 1006-1019. | 6.7 | 473 |
| 50 | Neuropeptides kill African trypanosomes by targeting intracellular compartments and inducing autophagic-like cell death. Cell Death and Differentiation, 2009, 16, 406-416. | 5.0 | 86 |
| 51 | Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis. Gut, 2009, 58, 929-939. | 6.1 | 594 |
| 52 | Chemical synthesis and characterization of silver-protected vasoactive intestinal peptide nanoparticles. Nanomedicine, 2009, 4, 919-930. | 1.7 | 23 |
| 53 | Adipose-Derived Mesenchymal Stem Cells Alleviate Experimental Colitis by Inhibiting Inflammatory and Autoimmune Responses. Gastroenterology, 2009, 136, 978-989. | 0.6 | 565 |
| 54 | Vasoactive intestinal peptide protects against Î²â€amyloidâ€induced neurodegeneration by inhibiting microglia activation at multiple levels. Glia, 2008, 56, 1091-1103. | 2.5 | 82 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | In vivo delivery of lentiviral vectors expressing vasoactive intestinal peptide complementary DNA as gene therapy for collagenâ€induced arthritis. Arthritis and Rheumatism, 2008, 58, 1026-1037. | 6.7 | 53 |
| 56 | Genetic association of vasoactive intestinal peptide receptor with rheumatoid arthritis: Altered expression and signal in immune cells. Arthritis and Rheumatism, 2008, 58, 1010-1019. | 6.7 | 50 |
| 57 | Vasoactive intestinal peptide inhibits cycloxygenase-2 expression in activated macrophages, microglia, and dendritic cells. Brain, Behavior, and Immunity, 2008, 22, 35-41. | 2.0 | 43 |
| 58 | Emergence of cortistatin as a new immunomodulatory factor with therapeutic potential in immune disorders. Molecular and Cellular Endocrinology, 2008, 286, 135-140. | 1.6 | 30 |
| 59 | Ghrelin Protects against Experimental Sepsis by Inhibiting High-Mobility Group Box 1 Release and by Killing Bacteria. Journal of Immunology, 2008, 180, 8369-8377. | 0.4 | 134 |
| 60 | Therapeutical Approaches of Vasoactive Intestinal Peptide as a Pleiotropic Immunomodulator. Current Pharmaceutical Design, 2007, 13, 1113-1139. | 0.9 | 80 |
| 61 | Therapeutic effect of cortistatin on experimental arthritis by downregulating inflammatory and Th1 responses. Annals of the Rheumatic Diseases, 2007, 66, 582-588. | 0.5 | 70 |
| 62 | Anti-inflammatory neuropeptide receptors: new therapeutic targets for immune disorders?. Trends in Pharmacological Sciences, 2007, 28, 482-491. | 4.0 | 46 |
| 63 | Tuning immune tolerance with vasoactive intestinal peptide: A new therapeutic approach for immune disorders. Peptides, 2007, 28, 1833-1846. | 1.2 | 32 |
| 64 | Vasoactive intestinal peptide and regulatory T-cell induction: a new mechanism and therapeutic potential for immune homeostasis. Trends in Molecular Medicine, 2007, 13, 241-251. | 3.5 | 73 |
| 65 | Emerging roles of vasoactive intestinal peptide: a new approach for autoimmune therapy. Annals of the Rheumatic Diseases, 2007, 66, iii70-iii76. | 0.5 | 40 |
| 66 | Adrenomedullin Protects from Experimental Arthritis by Down-Regulating Inflammation and Th1 Response and Inducing Regulatory T Cells. American Journal of Pathology, 2007, 170, 263-271. | 1.9 | 53 |
| 67 | Tuning inflammation with anti-inflammatory neuropeptides. Expert Opinion on Biological Therapy, 2007, 7, 461-478. | 1.4 | 20 |
| 68 | Therapeutic effect of urocortin on collagen-induced arthritis by down-regulation of inflammatory and Th1 responses and induction of regulatory T cells. Arthritis and Rheumatism, 2007, 56, 531-543. | 6.7 | 67 |
| 69 | Regulation of immune tolerance by anti-inflammatory neuropeptides. Nature Reviews Immunology, 2007, 7, 52-63. | 10.6 | 204 |
| 70 | Alternative transâ€splicing of the Trypanosoma cruzi LYT1 gene transcript results in compartmental and functional switch for the encoded protein. Molecular Microbiology, 2007, 65, 1559-1567. | 1.2 | 30 |
| 71 | Therapeutic Effect of a Poly(ADP-Ribose) Polymerase-1 Inhibitor on Experimental Arthritis by Downregulating Inflammation and Th1 Response. PLoS ONE, 2007, 2, e1071. | 1.1 | 40 |
| 72 | Therapeutic Effect of Vasoactive Intestinal Peptide on Experimental Autoimmune Encephalomyelitis. American Journal of Pathology, 2006, 168, 1179-1188. | 1.9 | 91 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Urocortin and Adrenomedullin Prevent Lethal Endotoxemia by Down-Regulating the Inflammatory Response. American Journal of Pathology, 2006, 168, 1921-1930. | 1.9 | 80 |
| 74 | Therapeutic Action of Ghrelin in a Mouse Model of Colitis. Gastroenterology, 2006, 130, 1707-1720. | 0.6 | 235 |
| 75 | Therapeutic Treatment of Experimental Colitis With Regulatory Dendritic Cells Generated With Vasoactive Intestinal Peptide. Gastroenterology, 2006, 131, 1799-1811. | 0.6 | 92 |
| 76 | Signaling mechanisms of vasoactive intestinal peptide in inflammatory conditions. Regulatory Peptides, 2006, 137, 67-74. | 1.9 | 28 |
| 77 | Vasoactive intestinal peptide induces regulatory dendritic cells that prevent acute graft-versus-host disease while maintaining the graft-versus-tumor response. Blood, 2006, 107, 3787-3794. | 0.6 | 94 |
| 78 | Vasoactive intestinal peptide generates human tolerogenic dendritic cells that induce CD4 and CD8 regulatory T cells. Blood, 2006, 107, 3632-3638. | 0.6 | 138 |
| 79 | Vasoactive Intestinal Peptide Generates CD4+CD25+ Regulatory T Cells in vivo: Therapeutic Applications in Autoimmunity and Transplantation. Annals of the New York Academy of Sciences, 2006, 1070, 190-195. | 1.8 | 20 |
| 80 | Vasoactive Intestinal Polypeptide Induces Regulatory Dendritic Cells That Prevent Acute Graft Versus Host Disease and Leukemia Relapse after Bone Marrow Transplantation. Annals of the New York Academy of Sciences, 2006, 1070, 226-232. | 1.8 | 9 |
| 81 | Vasoactive Intestinal Peptide: The Dendritic Cell -> Regulatory T Cell Axis. Annals of the New York Academy of Sciences, 2006, 1070, 233-238. | 1.8 | 28 |
| 82 | VIP Prevents Experimental Multiple Sclerosis by Downregulating Both Inflammatory and Autoimmune Components of the Disease. Annals of the New York Academy of Sciences, 2006, 1070, 276-281. | 1.8 | 31 |
| 83 | VIP: An Agent with License to Kill Infective Parasites. Annals of the New York Academy of Sciences, 2006, 1070, 303-308. | 1.8 | 19 |
| 84 | Protective Role for Plasmid DNA-Mediated VIP Gene Transfer in Non-Obese Diabetic Mice. Annals of the New York Academy of Sciences, 2006, 1070, 337-341. | 1.8 | 26 |
| 85 | Regulation of Dendritic Cell Differentiation by Vasoactive Intestinal Peptide: Therapeutic Applications on Autoimmunity and Transplantation. Annals of the New York Academy of Sciences, 2006, 1088, 187-194. | 1.8 | 30 |
| 86 | A Novel Mechanism for Immunosuppression: from Neuropeptides to Regulatory T Cells. Journal of NeuroImmune Pharmacology, 2006, 1, 400-409. | 2.1 | 29 |
| 87 | Vasoactive intestinal peptide induces CD4+,CD25+ T regulatory cells with therapeutic effect in collagen-induced arthritis. Arthritis and Rheumatism, 2006, 54, 864-876. | 6.7 | 93 |
| 88 | Vasoactive intestinal peptide induces regulatory T cells during experimental autoimmune encephalomyelitis. European Journal of Immunology, 2006, 36, 318-326. | 1.6 | 83 |
| 89 | Therapeutic effect of urocortin and adrenomedullin in a murine model of Crohn's disease. Gut, 2006, 55, 824-832. | 6.1 | 93 |
| 90 | Cortistatin, a new antiinflammatory peptide with therapeutic effect on lethal endotoxemia. Journal of Experimental Medicine, 2006, 203, 563-571. | 4.2 | 156 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Cortistatin, an antiinflammatory peptide with therapeutic action in inflammatory bowel disease. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 4228-4233. | 3.3 | 105 |
| 92 | Cortistatin as a potential multistep therapeutic agent for inflammatory disorders. Drug News and Perspectives, 2006, 19, 393. | 1.9 | 13 |
| 93 | Vasoactive intestinal peptide induces regulatory dendritic cells with therapeutic effects on autoimmune disorders. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 13562-13567. | 3.3 | 151 |
| 94 | The Neuropeptide Vasoactive Intestinal Peptide Generates Tolerogenic Dendritic Cells. Journal of Immunology, 2005, 175, 7311-7324. | 0.4 | 129 |
| 95 | Vasoactive intestinal peptide generates CD4+CD25+ regulatory T cells in vivo. Journal of Leukocyte Biology, 2005, 78, 1327-1338. | 1.5 | 99 |
| 96 | Vasoactive intestinal peptide family as a therapeutic target for Parkinsonâ€™s disease. Expert Opinion on Therapeutic Targets, 2005, 9, 923-929. | 1.5 | 12 |
| 97 | VIP/PACAP preferentially attract Th2 effectors through differential regulation of chemokine production by dendritic cells. FASEB Journal, 2004, 18, 1453-1455. | 0.2 | 99 |
| 98 | Trypanosoma cruzi macrophage infectivity potentiator has a rotamase core and a highly exposed Î±â€helix. EMBO Reports, 2002, 3, 88-94. | 2.0 | 42 |
| 99 | LYT1 Protein Is Required for Efficient In Vitro Infection by Trypanosoma cruzi. Infection and Immunity, 2001, 69, 3916-3923. | 1.0 | 56 |
| 100 | Toll-like receptor stimulation differentially regulates vasoactive intestinal peptide type 2 receptor in macrophages. Journal of Cellular and Molecular Medicine, 0, 13, 3209-3217. | 1.6 | 14 |